الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 239 |  |  |
| | | from | 239 | | |
Abstract
Asthma is a heterogeneous disease characterized by chronic inflammation of the airway defined by history recurrent respiratory symptoms such as wheezes cough and shortness of breath variable over time and intensity with variable expiratory airflow limitation (GINA 2019). The significant of eosinophilic inflammation in asthma is well established (Maestrelli et al., 2001). Allergen immunotherapy works like a vaccine. Patients receiving allergen immunotherapy are injected with increasing amounts of an allergen over several months. The body responds to the injected amounts of the allergen by developing an immunity or tolerance to it. As a result, allergy symptoms can be decreased or minimized when the patient is exposed to that allergen in the future. (Kündig et al., 2010). The aim of this study was to evaluate the early effects of subcutaneous allergen immunotherapy on the level of serum ECP and sputum eosinophil. This hospital-based case series study was conducted in Mansoura University Hospitals, Chest Medicine Department on Forty cases (40) of atopic asthma who attended to Mansoura University Asthma and Allergy clinic from January 2019 to January 2020. The study was accepted by Institutional Research Board (IRB) with a code number (MS.18.11. 353.R1).This study was conducted on 40 patients with asthma before and after 3 and 6 months of treatment with subcutaneous immunotherapy vaccines (SCIT). There were 6 patients excluded one patient diagnosed as T.B and 5 patients were lost during follow up. So, these results were done for 34 patients who fulfilled our inclusion criteria. The age of patients was 27.82 ± 6.28 years including, 19 females (55.9) and 26 patients from rural (76.5%) which was more prevalent.